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Abstract
Background: Genetic testing for an inherited susceptibility to cancer is an emerging technology in medical practice.
Little information is currently available about physicians’ attitudes towards these tests in developing countries.
Methods: We conducted an email survey of Nepalese physicians practicing in academic and non-academic settings in
Nepal, regarding knowledge, attitudes and perception towards genetic testing for gynaecologic cancer.
Results: Responses were received from 251 of 387 practitioners (65%). Only 46% of all respondents felt prepared to
answer patients’ questions about genetic testing for gynaecologic cancer, despite 80% reporting that patients had
asked questions about genetic testing, and 55% being asked more than 5 times in the past year. 42% reported more
than 10 of their patients having had genetic testing for cancer, the majority for BRCA1/2. Access (40%), cost (37%) and
lack of physicians’ information (24%) were cited as the main barriers to testing. The most commonly identified
concerns regarding genetic testing were the potential for increased patient anxiety, misinterpretation of results by
patients, and maintaining confidentiality of results (64%, 47% and 38% of respondents respectively).
Conclusion: This study shows the gap among the health care providers in developing countries and the available
modern scientific tools and skills in regard to the benefits of genetic testing for gynaecological cancers in a developing
nation. These findings indicate the need for the introduction of further genetic counselling education and support into
gynaecological care in Nepal.
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Background
It is known that a diagnosis of ovarian, fallopian tube,
peritoneal or endometrial cancer may be the first indica-
tor of a BRCA1 or BRCA2 mutation or Lynch Syndrome
due to germline mutations in one of the mismatch repair
genes: MLH1, MSH2, MSH6 or PMS2 [1, 2]. These syn-
dromes account for the majority of inherited gynaeco-
logical cancers. BRCA1/2 mutations account for 14% of
all non-mucinous ovarian cancer and 22% of the high
grade serous subtype [3]. Evidence of Lynch Syndrome is
found in 2% of ovarian cancer cases unselected for age
[4, 5] and 9% of endometrial cancer cases under the age
of 50 years [2, 6].
Identifying mutation carriers now has important im-
plications for the management of these gynaecological
cancers, as well as long term surveillance and risk re-
duction of other cancers. Additionally, at-risk relatives
can be offered testing, and appropriate risk manage-
ment if found to be mutation carriers, or reassured if
not. Gynaecologists and gynaecological oncologists
have a major role to play in not only identifying women
at risk of inherited cancer syndromes and referring ap-
propriate patients to genetic services, but also in man-
aging them appropriately [7].
The issue is much more complex than just referring
women for genetic testing and offering them prophylactic
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treatment. The genetics of hereditary gynaecological can-
cer is continually evolving and our understanding of the
molecular basis of inherited susceptibility to gynaeco-
logical cancer has improved considerably [8]. Thus, it is
the responsibility of clinicians to keep up to date with ad-
vances in this area, so as to support patients to make in-
formed decisions (Tables 1 and 2). A study from Australia
revealed that doctors feel it is their duty to inform individ-
uals at risk for hereditary cancer about the availability of
genetic counselling [9]. The doctors’ knowledge on the
subject, however, seemed to be suboptimal. Indeed, stud-
ies have shown that a high proportion of patients do not
receive adequate familial cancer risk assessment [10–12].
There has been a steady increase in the availability and ap-
plication of genetic tests during the past decade [13]. In
the USA genetic testing for hereditary cancer is offered by
multiple private laboratories. The cost of testing is gener-
ally covered by the patient’s health insurer, while in United
Kingdom, hereditary cancer genetic testing is covered by
the National Health Service. Cancer predisposition genetic
testing is not covered by Australia’s national healthcare
provider, Medicare, but through the public genetic service
ordering the test. Each nation has national guidelines for
eligibility for funded testing, with many offering mutation
searching where there is an estimated likelihood of finding
a mutation of at least 10%.
Genetic testing for susceptibility for gynaecological
cancers is widely available in western countries, whereas
in developing countries it is still in a rudimentary level.
In Nepal National Academy of Medical Sciences, Bir
Hospital is in the process of establishing a genetic la-
boratory. Currently, Nepalese patients are referred to
India for genetic testing, where the current cost of
BRCA1/2 testing is approximately US$1400.
The hereditary cancer burden in Nepal is unknown,
however a recent study of 50 women with breast cancer
diagnosed in Kathmandu found the prevalence of a sin-
gle mutation (BRCA1 185delAG) to be 8%, which is con-
siderably higher than in unselected breast cancer cases
in a western population [14], suggesting that hereditary
cancer may be just as common, if not more so, than in
other populations. Compared with the western devel-
oped countries, genetic testing and risk assessment for
familial cancer in Asia has been shown to be less avail-
able, thus prohibiting the appropriate surveillance, clin-
ical strategies and cancer management of patients and
their relatives [15].
Nepal has a population of 27.8 million, and a land area
of 147,181 km2. The size of the country, relative in-
accessibility of mountainous regions and the demo-
graphic factors all contribute to difficulties in providing
accurate cancer statistics. No population based cancer
registry program exists to assess the incidence, preva-
lence, morbidity and mortality of cancer. The import-
ance of cancer registry data for development of national
cancer control programs has been stressed in the con-
text of South Asia [16]. Pooling the cases presented in
the main urban centres has been used as a surrogate for
Table 1 Risk management for an Unaffected Female BRCA1/2 Mutation Carrier
Cancer type Recommendation
Breast Surgical ▪ offer bilateral risk-reducing mastectomy followed by self-surveillance of breast area. The greatest
benefit is predicted when surgery occurs at age ≤40 years
▪ alternatively in the absence of bilateral risk-reducing mastectomy, recommend RRSO preferably
around age 40 years
Surveillance ▪ in families with breast cancer diagnosed under age 35 years, individualised screening
recommendations may apply
▪ otherwise screening should start at age 30 years
▪ 30–50 years – annual MRI + MMG (+/− US)
▪ >50 years – annual MMG +/− US
▪ pregnant - no MRI or MMG, consider US
Risk-reducing medication ▪ careful assessment of risks and benefits in the individual case by an experienced medical
professional is required when considering the use of medication, such as tamoxifen or
raloxifene to reduce risk of developing breast cancer in unaffected women. See Cancer
Australia Risk-reducing medication resource
Ovarian/fallopian tube Surgical ▪ recommend RRBSO after family completion or around age 40 years3 with peritoneal lavage
and close histological examination to exclude occult malignancy
Surveillance ▪ do not offer serum CA125 and/or transvaginal ultrasound (TVU)
Pancreatic ▪ no evidence of benefit from surveillance
https://www.eviq.org.au Risk Management for an unaffected Female BRCA1 Mutation Carrier
https://www.eviq.org.au Risk Management for an unaffected Female BRCA2 Mutation Carrier
Abbreviations: RRSO: Risk-reducing salpingo-oophorectomy, RRBSO: Risk-reducing bilateral salpingo-oophorectomy, US: ultrasound, MMG: mammogram (digital if
available), MRI: magnetic resonance imaging
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a central cancer registry; however these figures are likely
to be an underestimate of incidence, as many of the pa-
tients go to India or abroad for their further treatment.
A hospital based cancer registry (HBCR) program was
started from 1997 in 3 cancer diagnosing and treating
hospitals in Kathmandu. Since 2003, with the support of
WHO-Nepal, the HBCR program has expanded to cover
seven major cancer diagnosis and treatment hospitals in
Nepal, which are cooperating to provide relevant data
coordinated by the BP Koirala Memorial Cancer
Hospital. An initial assessment of incidence at 4 major
hospitals found that of 2340 cancers in females overall
in 2004, the most common site was cervix uteri (21%),
followed by breast (16%), lung (11%) and ovary (6%).
However breast and ovarian were the most common
cancers amongst women aged 15–34 [17]. This high in-
cidence at young ages raises the possibility of an inher-
ited basis for some of these cancers. In 2012, almost
4000 female cancer cases were registered amongst 7
hospitals, with the most prevalent age group being 50–54
years (12.8%). There was a decrease in cervical and lung
cancers, but an increase in breast cancers [18].
There is currently no specialised hereditary cancer
service. The level of knowledge of hereditary cancer
amongst practitioners seeing women with gynaecological
cancer in Nepal is unknown. It is also unknown if these
practitioners are currently referring women for genetic
testing, and if so, to where. The present study is the first
of its kind to be conducted among the Nepalese
practitioners regarding the awareness and knowledge
about genetic testing of patients with gynaecological ma-
lignancy diagnosis.
Method
A self-administered 15 min survey consisting of 23 ques-
tions was designed after a focus group discussion among
doctors working at the B.P. Koirala Institute of Health
Sciences (BPKIHS) and a literature search of similar
topics (Additional file 1). The questionnaire included
demographic characteristics, physician practice parame-
ters of speciality, patients seen per week, years of prac-
tice and practice setting.
Questionnaires were emailed to 387 general practi-
tioners and specialists of government and private hospi-
tals in Nepal. Their fields included Gynaecologic
Oncology, General Gynaecology, Internal Medicine,
Family Medicine, Community Medicine/Public health
and Primary Care. Practitioners were identified through
the Nepal Society of Obstetricians and Gynaecologists
and the faculties of the B.P. Koirala Institute of Health
Sciences (BPKIHS).
The questionnaire was sent with a cover letter explain-
ing the aims of the study and reassuring the respondents
that their responses would be de-identified. Two re-
minder emails were sent to non-responders at two-week
intervals. The email also gave the option of requesting
another questionnaire if the original one had been mis-
placed/discarded.
Table 2 Lynch Syndrome risk management guidelines. All patients should be entered on a local hereditary cancer registry for
information and surveillance reminders
Cancer type Recommendations
Colorectal Surgical ▪ consider subtotal colectomy in selected individuals
Surveillance MSH6/PMS2 ▪ annual colonoscopy from age 30 years or 5 years younger than youngest affected
if <35 years
▪ review frequency of colonoscopy at age 60 years with a view to
reduced frequency
Surveillance MLH1/MSH2 ▪ annual colonoscopy from age 25 years or 5 years younger than youngest affected
if <30 years
▪ review frequency of colonoscopy at age 60 years with a view to 2nd yearly frequency
Risk-reducing medication ▪ there may be a reduction of risk in taking aspirin however the appropriate dose is not
yet defined (preliminary data)
Endometrial Surgical ▪ recommend hysterectomy after childbearing complete or from age 40 years, or 5 years
younger than the youngest affected, whichever comes first
Surveillance ▪ there is no evidence for transvaginal ultrasound (TVU) and/or aspiration biopsy
Ovarian Surgical ▪ recommend risk reducing salpingo-oophorectomy (RRSO) at time of hysterectomy
▪ recommend HRT at the time of RRSO and continue until the usual time of menopause
Surveillance ▪ do not offer serum CA125 and/or transvaginal ultrasound (TVU). See Cancer Australia for
further information
Gastric Surveillance ▪ consider second yearly gastroscopy from age 30 years in families with gastric cancer or
those at high ethnic risk - e.g. Chinese, Korean, Chilean and Japanese
Urothelial Surveillance ▪ no evidence of benefit but patients encouraged to report symptoms e.g. haematuria
https://www.eviq.org.au Risk Management for Lynch Syndrome
Pokharel et al. Gynecologic Oncology Research and Practice  (2016) 3:12 Page 3 of 6
Doctors’ consent to participate was inferred by com-
pletion and return of the questionnaire.
The study was approved by the UNSW Human Re-
search Ethics Advisory (HREA) Panel, University of New
South Wales, Sydney, Project number-HC16248.
Results
Responses were received from 251 of 387 practitioners
(65%) – 118 gynaecologists (47%), 36 gynaecological on-
cologists (14%) and 97 clinicians from other fields (39%).
There was a trend for gynaecologists to be older (36%
aged over 50, vs 17% both of gynaecological oncologists
and other clinicians) and more likely to be female (72%
vs 33% of gynaecological oncologists and 47% of other
clinicians), but differences did not reach significance.
Overall, half of the respondents saw less than 3 pa-
tients per week regarding gynaecological cancer (which
included 30% of non-gynaecologists who reported seeing
none). No respondent reported seeing more than 10 gy-
naecological cancer patients per week, with 64% of gy-
naecological oncologists, 90% of gynaecologists and all
clinicians from other fields seeing less than 6 patients
per week regarding gynaecological cancer (Fig. 1).
Approximately half of all respondents felt prepared to
answer patient’s questions about genetic testing for gynae-
cologic cancer (46%). However, while 94% of gynaecologic
oncologists felt prepared, only 47% of gynaecologists
and 26% of other clinicians did so, despite 86% of
gynaecologists and 71% of other clinicians reporting
that patients had asked questions about genetic testing.
Non-gynaecologic clinicians had lower requests for in-
formation with a third reporting never being asked, and
half being asked on less than 5 occasions in the past
year. Gynaecologists and gynaecological-oncologists
had similar requests with around 58% of each group
reporting less than 5 requests in the past year and 39%
and 36% respectively being asked on 6–10 occasions.
All groups demonstrated a bimodal distribution of the
number of patients having had genetic testing for cancer
predisposition, with overall 40% reporting less than 6 pa-
tients having had testing and 42% reporting more than
10 of their patients having had genetic testing for cancer.
The majority of tests were for BRCA1/2 (70%), with 10%
for mismatch repair genes (Lynch Syndrome) and 22%
reporting other genetic tests. 27% of respondents reported
that the results never influenced management, 45% said
that they did sometimes and 27% said most of the time.
Access (40%), cost (37%) and lack of physicians’ infor-
mation (24%) were cited as the main barriers to testing.
When asked about how genetic test results influenced
their patients’ care, preventive surgery was the most
cited option (47%) followed by screening (33%), lifestyle
changes (31%) and medication (14%). The vast majority
of respondents thought that genetic testing was clinically
useful. Of the 23 respondents who did not think genetic
testing was clinically useful, the majority (n = 17) were
non gynaecological clinicians. They cited difficulties in
interpreting results, failure to affect patient care and pa-
tient anxiety as the main reasons. Amongst all respon-
dents, the most commonly identified concerns regarding
genetic testing were the potential for increased patient
anxiety, misinterpretation of results by patients, and
maintaining confidentiality of results (64%, 47% and 38%
of respondents respectively). Approximately one quarter
of all respondents noted concerns regarding the
provision of post-test counselling, the potential for dis-
crimination, the clinical utility of results, and the accur-
acy of results. However, 91% of all respondents said that
if a patient brought genetic test results, it would be likely
or very likely to influence their care.
Discussion
This is the first analysis of Nepalese clinicians regarding
genetic testing for gynaecological cancer. Similar to
Baars MJ et al. [19] who surveyed Dutch medical practi-
tioners regarding genetic testing in 2005, we had a pleas-
ing response rate of 65%. Our findings should however
be viewed in light of several limitations. We have no cri-
teria to estimate if decliners would answer differently to
our respondents. The replies are self-reported with no
objective measures, and sub group analysis was limited
by the sample size.
Our cohort reported low preparedness to answer pa-
tients’ questions about genetic testing for gynaecological
cancer, particularly from non-gynaecologists. Remaining
respondents were primary care physicians (39%), which
is consistent with a study conducted by Keating NL et
al., [20] where it was emphasized that wider participa-
tion by community-based physicians successfully incor-
porated genetic testing into practice. The trend is seen
that with their involvement, chances of early detection
care and referral will increase. This will ultimately
Fig. 1 Number of Gynaecological cancer patients seen per week by
the clinicians
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facilitate and increase the promotion of genetic testing
facilities, and expand Gynaecologists’ role in counsel-
ling and testing.
Self-reported utilisation of genetic information was
high. This cohort has experienced the need for better
clinicians’ education and confidence to discuss results. A
number of the issues concerning patient anxiety and
confidentiality may be improved by more extensive use
of genetic counsellors in the testing process. Western
models of care include genetic counsellors as a source of
assessment and care of patients suitable for genetic as-
sessment, and our findings that less than half of gynae-
cologists and a quarter of other clinicians feel prepared
to answer questions about genetic testing for hereditary
cancer, indicate that there is a need for genetic profes-
sionals to assist clinicians in Nepal. The limited access
to genetic counsellors is unlikely to change with no ter-
tiary institution in Nepal currently offering this course.
Access and cost of genetic testing may not be such sig-
nificant barriers with the establishment of the planned
genetic service in Nepal. Additionally, the ongoing re-
duction in the cost of testing panels of multiple genes
through next generation sequencing, combined with the
ease of saliva and cheek swab testing, is anticipated to
facilitate Nepalese doctors ordering testing for hereditary
cancers in the future.
Our survey of the Royal Hospital for Women in
Sydney [21], found that 23% of all gynaecological can-
cer patients warranted a genetic assessment. At this
hospital, a Hereditary Cancer expert attends all
Tumour Board meetings and this allows optimal iden-
tification of patients requiring genetic assessment.
Almost half of the respondents cited possible misinter-
pretation of results by patients as a concern, further
highlighting a need for genetic counselling expertise.
Until there are data on the prevalence of hereditary
gynaecological cancer in Nepal, estimates of the need for
improved genetic care need to be based on outside data.
A comparison of the BPKMCH 2010–2012 annual re-
port compared with a recent audit of cases from Sydney
[21], indicates there are approximately twice as many gy-
naecological cancer patients seen at BPKMCH compared
with the Royal Hospital for Women. If the mutation
prevalence is similar to that of Australia, 20 women di-
agnosed with gynaecological cancer in BPKMCH each
year would be found to carry either a BRCA1/2 or MMR
mutation, providing the opportunity for improved care
for themselves and their relatives.
We did not enquire about frequency of patients
reporting a family history of relevant cancers, as partici-
pant recall may not have been robust. A future prospect-
ive audit of consultations from a similar cohort would
provide further data to assess the need for hereditary
cancer services in Nepal.
In Nepal women diagnosed with gynaecological cancer
are treated by general gynaecologists and the women
who are referred to Nepal Cancer Hospital and Research
centre, Bhaktapur Cancer Hospital and B.P. Koirala
Memorial Cancer Hospital are treated by Gynaecologists
with additional expertise in Gynaeoncology. There are
very few specialist gynaecological Oncologists in Nepal.
Conclusion
This survey highlights clinicians’ concerns about genetic
testing for hereditary gynaecological cancer in Nepal,
and provides a basis for consideration of measures to
improve knowledge and consideration of testing for af-
fected Nepalese women and their families.
Additional file
Additional file 1: Awareness towards genetic testing for gynaecologic
cancer among the medical service providers in Nepal. (DOCX 17 kb)
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